Evidence map›Paper›PMID 33947214›Full record

ArticleStroke2021

TREM (Triggering Receptor Expressed on Myeloid Cells)-1 Inhibition Attenuates Neuroinflammation via PKC (Protein Kinase C) δ/CARD9 (Caspase Recruitment Domain Family Member 9) Signaling Pathway After Intracerebral Hemorrhage in Mice.

Qin Lu, Rui Liu, Prativa Sherchan, Reng Ren, Wei He, Yuanjian Fang, Yi Huang, Hui Shi, Lihui Tang, Shuxu Yang and 2 more

Open access · greenAbstract read
In one paragraph

Article in Stroke, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Qin Lu *Department of Neurosurgery, Sir Run Run Shaw Hospital (Q.L., S.Y.), School of Medicine, Zhejiang University, Hangzhou, China.
Rui Liu *Department of Neurosurgery, The Second Affiliated Hospital (R.R., Y.F., Y.H., L.T.), School of Medicine, Zhejiang University, Hangzhou, China.
Prativa SherchanDepartment of Physiology and Pharmacology (Q.L., R.L., P.S., R.R., W.H., Y.F., Y.H., H.S., L.T., J.H.Z., J.T.), Loma Linda University, CA.
Reng RenDepartment of Physiology and Pharmacology (Q.L., R.L., P.S., R.R., W.H., Y.F., Y.H., H.S., L.T., J.H.Z., J.T.), Loma Linda University, CA.
Wei HeDepartment of Physiology and Pharmacology (Q.L., R.L., P.S., R.R., W.H., Y.F., Y.H., H.S., L.T., J.H.Z., J.T.), Loma Linda University, CA.
Yuanjian FangDepartment of Neurosurgery, The Second Affiliated Hospital (R.R., Y.F., Y.H., L.T.), School of Medicine, Zhejiang University, Hangzhou, China.
Yi HuangDepartment of Neurosurgery, The Second Affiliated Hospital (R.R., Y.F., Y.H., L.T.), School of Medicine, Zhejiang University, Hangzhou, China.
Hui ShiDepartment of Physiology and Pharmacology (Q.L., R.L., P.S., R.R., W.H., Y.F., Y.H., H.S., L.T., J.H.Z., J.T.), Loma Linda University, CA.
Lihui TangDepartment of Neurosurgery, The Second Affiliated Hospital (R.R., Y.F., Y.H., L.T.), School of Medicine, Zhejiang University, Hangzhou, China.
Shuxu YangDepartment of Neurosurgery, Sir Run Run Shaw Hospital (Q.L., S.Y.), School of Medicine, Zhejiang University, Hangzhou, China.
John H ZhangDepartment of Physiology and Pharmacology (Q.L., R.L., P.S., R.R., W.H., Y.F., Y.H., H.S., L.T., J.H.Z., J.T.), Loma Linda University, CA.
Jiping TangDepartment of Physiology and Pharmacology (Q.L., R.L., P.S., R.R., W.H., Y.F., Y.H., H.S., L.T., J.H.Z., J.T.), Loma Linda University, CA.
Loma Linda University · USCouncil of Independent Colleges · USSir Run Run Shaw Hospital · CN

Funding

Harnessing Endogenous Neuroprotection Following ICHR01NS091042 · NINDS · LOMA LINDA UNIVERSITY · PI ZHANG, JOHN H · 2016 to 2020
$1.7M
Investigating the role of mast cells in neonatal germinal matrix hemorrhageR21NS101284 · NINDS · LOMA LINDA UNIVERSITY · PI TANG, JIPING · 2017 to 2018
$435k
NINDS NIH HHS R01 NS091042NINDS NIH HHS R21 NS101284
6 · The paper itself

Abstract

Background and Purpose: Intracerebral hemorrhage (ICH) is a devastating subtype of stroke with high mortality and disability. Inflammatory response promotes secondary brain injury after ICH. TREM (triggering receptor expressed on myeloid cells)-1 is a key regulator of inflammation. The aim of this study was to evaluate the role of TREM-1 in neuroinflammatory response after ICH in mice. Methods: CD1 mice (n=275) were used in this study. Mice were subjected to ICH by autologous blood injection. TREM-1 knockout CRISPR was administered intracerebroventricularly to evaluate the role of TREM-1 after ICH. A selective TREM-1 inhibitor, LP17, was administered intranasally 2 hours after ICH. To elucidate TREM-1 signaling pathway, CARD9 (caspase recruitment domain family member 9) activation CRISPR was administered with LP17 and TREM-1 activating anti-mouse TREM-1 monoclonal antibody (mAb) was administered with Rottlerin, a specific PKC (protein kinase C) δ inhibitor. Lastly, to evaluate the role of HMGB1 (high-mobility group box 1) in TREM-1 mediated microglia activation, glycyrrhizin, an inhibitor of HMBG1 was administered with TREM-1 activating mAb. Neurobehavioral test, brain water content, Western blot, immunofluorescence staining, and coimmunoprecipitation was performed. Results: TREM-1 knockout reduced ICH-induced neurobehavioral deficits and neuroinflammatory response. The temporal expression of HMGB1, TREM-1, PKC δ, and CARD9 increased after ICH. TREM-1 was expressed on microglia. Intranasal administration of LP17 significantly decreased brain edema and improved neurobehavioral outcomes at 24 and 72 hours after ICH. LP17 promoted M2 microglia polarization and reduced proinflammatory cytokines after ICH, which was reversed with CARD9 activation CRISPR. TREM-1 mAb increased neurobehavior deficits, proinflammatory cytokines, and reduced M2 microglia after ICH, which was reversed with Rottlerin. HMBG1 interaction with TREM-1 increased after ICH, and glycyrrhizin reduced neuroinflammation and promoted M2 microglia which was reversed with TREM-1 mAb. Conclusions: This study demonstrated that TREM-1 enhanced neuroinflammation by modulating microglia polarization after ICH, and this regulation was partly mediated via PKC δ/CARD9 signaling pathway and increased HMGB1 activation of TREM-1.

Indexed as

Signal TransductionAnimalsCARD Signaling Adaptor ProteinsCerebral HemorrhageCRISPR-Cas SystemsGene Knockdown TechniquesInflammationMaleMiceProtein Kinase C-deltaTriggering Receptor Expressed on Myeloid Cells-1Card9 protein, mouseCARD Signaling Adaptor ProteinsPrkcd protein, mouseProtein Kinase C-deltaTREM1 protein, mouseTriggering Receptor Expressed on Myeloid Cells-1cerebral hemorrhageinflammationmicrogliasignaling pathwaytriggering receptor expressed on myeloid cells 1

Identifiers

PMID33947214
PMCPMC8321132
OpenAlexW3157269212

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.